Details:

Alternative Title:
J Acquir Immune Defic Syndr
Publisher's site:
http://dx.doi.org/10.1097/QAI.0000000000002398
Personal Author:
Crepaz, Nicole ; Song, Ruiguang ; Lyss, Sheryl ; Hall, H. Irene
Crepaz, Nicole ; Song, Ruiguang ; Lyss, Sheryl ; Hall, H. Irene Less -
Description:
Background:

Since 2012, treatment guidelines have recommended initiating antiretroviral therapy for all persons as soon as possible after HIV diagnosis, irrespective of CD4 counts. If clinicians adopted the treatment guidelines, a shortened interval between diagnosis and first viral suppression (Dx-to-VS) would be expected, with greater declines among those with CD4 counts ≥500 cells/μL at diagnosis.

Methods:

Using the National HIV Surveillance System data, we examined Dx-to-VS intervals among persons aged ≥13 years with HIV infection diagnosed during 2012–2017. Analyses were stratified by the first CD4 count: CD4 ≥500 cells/μL, 200–499 cells/μL, <200 cells/μL, and no CD4 value reported within 3 months after diagnosis.

Results:

During 2012–2017 in the 27 US jurisdictions with complete laboratory reporting, 138,759 HIV diagnoses occurred. The median Dx-to-VS interval shortened overall for persons with HIV diagnosed in 2012 vs. 2017 from 9 to 5 months, a 12.3% annual decrease (P < 0.001) and in all CD4 groups. In 2012, the Dx-to-VS interval was longer for persons with CD4 ≥500 cells/μL than 200–499 cells/μL and <200 cells/μL (median, 9, 7, and 6 months, respectively). By 2017, the median interval was 4 months for these groups, compared with 25 months for those without a CD4 value within 3 months after diagnosis.

Conclusion:

Decreases in Dx-to-VS intervals across all CD4 groups with a greater decrease among those with CD4 ≥500 cells/μL are consistent with the implementation of treatment recommendations. The Dx-to-VS interval was longest among persons not linked to care within 3 months after diagnosis, underscoring the importance of addressing barriers to linkage to care for ending the HIV epidemic.


Subject:
[+]
Adolescent
Adult
Anti-HIV Agents
CD4 Lymphocyte Count
Drug Administration Schedule
Female
HIV-1
HIV Infections
Humans
Male
Middle Aged
Time Factors
Viral Load
Young Adult

Source:
J Acquir Immune Defic Syndr. 85(1):46-50
Pubmed ID:
32379083
Pubmed Central ID:
PMC9647153
Document Type:
Journal Article
Funding:
CC999999/ImCDC/Intramural CDC HHSUnited States/
Place as Subject:
United States
Collection(s):
CDC Public Access
Main Document Checksum:
[+]
urn:sha256:41ab214a608b2f0db2c806a6836cf1f7952d9e2cff13a6993cc373437cf750a2
File Type:

Supporting Files

• nihms-1838908.nxml

  xml

More +